166372-04-9

Upstream product

• 2216-92-4 N-phenylglycine ethyl ester 
• 65018-90-8 (1aR-cis)-1a,7b-dihydro-2,2-dimethyl-2H-oxireno[c][1]benzopyran-6-carbonitrile 
• 62-53-3 aniline 

Downstream Products

• 185690-31-7 2-[((3R,4S)-6-Cyano-3-hydroxy-2,2-dimethyl-chroman-4-yl)-phenyl-amino]-N-(2,2-dimethoxy-ethyl)-acetamide 
• 185690-32-8 2-[((3R,4S)-6-Cyano-3-hydroxy-2,2-dimethyl-chroman-4-yl)-phenyl-amino]-N-(2-oxo-ethyl)-acetamide 

Relevant academic research and scientific papers

Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity

This paper describes our studies aimed at the discovery of structurally distinct analogs of the cardioprotective K(ATP) opener BMS-180448 (2) with improved selectivity for the ischemic myocardium. The starting compound 6, derived from the indole analog 4, showed good cardioprotective potency and excellent selectivity compared to 2 and the first-generation K(ATP) opener cromakalim (1). The structure-activity studies indicate that increasing the size of the alkyl ester leads to diminished potency as does its replacement with a variety of other groups (nitrile, methyl sulfone). Replacement of the ethyl ester of 6 with an imidazole gave the best compound 3 (BMS-191095) of this series which maintains the potency and selectivity of its predecessor 6. The results described in this publication further support that there is no correlation between vasorelaxant and cardioprotective potencies of K(ATP) openers. Compound 3 is over 20- and 4000-fold more selective for the ischemic myocardium than 2 and cromakalim (1), respectively. The selectivity for the ischemic myocardium is achieved by reduction of vasorelaxant potency rather than enhancement in antiischemic potency. As for cromakalim (1) and 2, the cardioprotective effects of compound 3 are inhibited by cotreatment with the K(ATP) blocker glyburide, indicating that the K(ATP) opening is involved in its mechanism of cardioprotection. With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.